NYSE:PFE - Pfizer Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $40.07
  • Forecasted Upside: 9.04 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 10 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$36.75
▼ -0.11 (-0.30%)
1 month | 3 months | 12 months
Get New Pfizer Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PFE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PFE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$40.07
▲ +9.04% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is $40.07, with a high forecast of $53.00 and a low forecast of $24.00. The average price target represents a 9.04% upside from the last price of $36.75.
Hold
The current consensus among 14 contributing investment analysts is to hold stock in Pfizer. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 16 hold ratings
  • 0 sell ratings
7/24/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 13 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 10 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 10 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 0 sell ratings
12/15/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 0 sell ratings
1/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2021The Goldman Sachs GroupSet Price TargetNeutral$40.00Low
i
1/4/2021Royal Bank of CanadaSet Price TargetNeutral$42.00N/A
i
12/29/2020Royal Bank of CanadaReiterated RatingNeutral$42.00N/A
i
12/16/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$43.00 ➝ $42.00N/A
i
12/11/2020The Goldman Sachs GroupSet Price TargetNeutral$40.00Low
i
12/4/2020BarclaysBoost Price TargetEqual Weight$35.00 ➝ $37.00Low
i
12/2/2020BarclaysSet Price TargetNeutral$35.00Medium
i
12/2/2020Royal Bank of CanadaSet Price TargetBuy$43.00Low
i
12/2/2020The Goldman Sachs GroupSet Price TargetNeutral$40.00Low
i
11/19/2020The Goldman Sachs GroupInitiated CoverageNeutral$40.00Medium
i
11/10/2020Sanford C. BernsteinInitiated CoverageMarket Perform$42.00High
i
11/10/2020MizuhoBoost Price TargetBuy$43.00 ➝ $44.00High
i
Rating by Vamil Divan at Mizuho
11/9/2020BarclaysReiterated RatingNeutral$35.00High
i
11/9/2020JPMorgan Chase & Co.Set Price TargetNeutral$36.00High
i
10/28/2020SVB LeerinkBoost Price TargetMarket Perform$42.00 ➝ $43.00High
i
Rating by G. Porges at SVB Leerink LLC
10/23/2020TruistInitiated CoverageBuy$42.00Low
i
10/16/2020Royal Bank of CanadaSet Price TargetBuy$43.00Low
i
10/12/2020Atlantic SecuritiesDowngradeOverweight ➝ Neutral$44.00 ➝ $39.00Low
i
9/29/2020Berenberg BankInitiated CoverageHold$38.00Low
i
9/15/2020MizuhoReiterated RatingBuy$43.00Low
i
Rating by Vamil Divan at Mizuho
9/9/2020Royal Bank of CanadaSet Price TargetBuy$43.00Low
i
7/30/2020Morgan StanleyBoost Price TargetEqual Weight$36.00 ➝ $42.00Low
i
Rating by David Risinger at Morgan Stanley
7/29/2020UBS GroupBoost Price TargetNeutral$37.00 ➝ $39.00Low
i
7/29/2020SVB LeerinkBoost Price TargetMarket Perform$39.00 ➝ $42.00Low
i
Rating by G. Porges at SVB Leerink LLC
7/28/2020MizuhoReiterated RatingPositive ➝ Buy$38.00Low
i
Rating by Vamil Divan at Mizuho
7/21/2020Morgan StanleyReiterated RatingHold$36.00High
i
Rating by David Risinger at Morgan Stanley
7/20/2020Royal Bank of CanadaReiterated RatingBuy$43.00High
i
6/29/2020MizuhoInitiated CoverageBuy$38.00Low
i
Rating by Vamil Divan at Mizuho
6/26/2020Piper SandlerBoost Price Target$18.50 ➝ $24.00Medium
i
6/16/2020SVB LeerinkInitiated CoverageMarket Perform$40.00Low
i
Rating by G. Porges at SVB Leerink LLC
6/1/2020BarclaysLower Price Target$37.00 ➝ $35.00Medium
i
6/1/2020JPMorgan Chase & Co.Lower Price TargetNeutral$37.00 ➝ $36.00High
i
5/18/2020MizuhoReiterated RatingBuy$42.00Low
i
Rating by Vamil Divan at Mizuho
4/29/2020BarclaysBoost Price TargetEqual Weight$36.00 ➝ $37.00Low
i
4/27/2020Royal Bank of CanadaReiterated RatingBuy$44.00Medium
i
4/26/2020MizuhoReiterated RatingBuy$42.00High
i
Rating by Vamil Divan at Mizuho
4/2/2020Morgan StanleyLower Price TargetEqual Weight$43.00 ➝ $36.00Medium
i
3/27/2020Royal Bank of CanadaLower Price TargetOutperform$46.00 ➝ $44.00Low
i
3/19/2020Cantor FitzgeraldReiterated RatingBuy$53.00High
i
Rating by Louise Chen at Cantor Fitzgerald
3/18/2020MizuhoReiterated RatingBuy$42.00High
i
Rating by Vamil Divan at Mizuho
2/27/2020Standpoint ResearchUpgradeHold ➝ BuyHigh
i
2/27/2020BarclaysInitiated CoverageEqual Weight$36.00Medium
i
2/5/2020MizuhoInitiated CoverageBuy$42.00Low
i
1/29/2020Cantor FitzgeraldReiterated RatingBuy$53.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
1/28/2020JPMorgan Chase & Co.Reiterated RatingNeutral$37.00Low
i
1/6/2020Royal Bank of CanadaInitiated CoverageOutperform$46.00Medium
i
11/6/2019Credit Suisse GroupReiterated RatingHold$41.30Low
i
10/29/2019JPMorgan Chase & Co.Reiterated RatingNeutralHigh
i
Rating by Chris Schott at JPMorgan Chase & Co.
10/16/2019Bank of AmericaInitiated CoverageNeutral$37.00Low
i
9/19/2019JPMorgan Chase & Co.Boost Price TargetNeutral$37.00 ➝ $46.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
8/28/2019DZ BankUpgradeSell ➝ Hold$36.00Medium
i
8/27/2019Morgan StanleyLower Price TargetEqual Weight$40.00 ➝ $38.00High
i
8/27/2019DZ BankReiterated RatingHold ➝ NeutralMedium
i
8/12/2019Credit Suisse GroupReiterated RatingHold ➝ NeutralHigh
i
8/5/2019UBS GroupReiterated RatingNeutral$43.00High
i
7/30/2019Bank of AmericaDowngradeBuy ➝ NeutralHigh
i
7/30/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$48.00 ➝ $40.00High
i
7/29/2019JPMorgan Chase & Co.Set Price TargetNeutral$46.00High
i
Rating by Chris Schott at JPMorgan Chase & Co.
7/23/2019JPMorgan Chase & Co.Reiterated RatingNeutral$46.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
7/15/2019Credit Suisse GroupInitiated CoverageHold$47.00Low
i
6/17/2019Credit Suisse GroupReiterated RatingBuy$48.00Low
i
6/17/2019The Goldman Sachs GroupReiterated RatingBuy$49.00Low
i
6/17/2019JPMorgan Chase & Co.Reiterated RatingHold$46.00Low
i
6/4/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$48.00Low
i
5/28/2019The Goldman Sachs GroupInitiated CoverageConviction-BuyLow
i
5/9/2019BarclaysReiterated RatingHold$41.00Low
i
5/6/2019Credit Suisse GroupReiterated RatingBuy$48.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
4/30/2019JPMorgan Chase & Co.Set Price TargetNeutral$46.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
4/19/2019JPMorgan Chase & Co.Reiterated RatingNeutral$46.00N/A
i
Rating by Chris Schott at JPMorgan Chase & Co.
4/1/2019Bank of AmericaBoost Price TargetBuy ➝ Buy$45.00 ➝ $48.00Low
i
2/20/2019CitigroupReiterated RatingSell ➝ Neutral$41.00Medium
i
Rating by Andrew Baum at Citigroup Inc.
2/19/2019Cantor FitzgeraldReiterated RatingBuy$53.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
1/31/2019ArgusUpgradeHold ➝ Buy$55.00Medium
i
1/31/2019Credit Suisse GroupUpgradeNeutral ➝ OutperformMedium
i
Rating by Vamil Divan at Credit Suisse Group AG
1/28/2019Credit Suisse GroupReiterated RatingNeutral$45.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
1/23/2019UBS GroupDowngradeBuy ➝ NeutralLow
i
1/1/2019Credit Suisse GroupSet Price TargetNeutral$45.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
12/30/2018Cantor FitzgeraldSet Price TargetBuy$53.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
12/26/2018Credit Suisse GroupSet Price TargetNeutral$45.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
12/20/2018Credit Suisse GroupReiterated RatingNeutral$45.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
12/13/2018Credit Suisse GroupSet Price TargetHold$45.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
12/11/2018Cantor FitzgeraldReiterated RatingBuy$53.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
12/11/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$46.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
11/27/2018Atlantic SecuritiesReiterated RatingBuy$54.00Medium
i
11/26/2018Credit Suisse GroupSet Price TargetHold$42.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
11/19/2018Cantor FitzgeraldReiterated RatingBuy$53.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
11/8/2018Cantor FitzgeraldSet Price TargetBuy$53.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
11/6/2018CitigroupBoost Price TargetSell ➝ Sell$34.00 ➝ $37.00Medium
i
11/1/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$47.00 ➝ $46.00Medium
i
11/1/2018Societe GeneraleSet Price TargetHold$43.00Medium
i
Rating by Florent Cespedes at Societe Generale
10/30/2018Credit Suisse GroupReiterated RatingNeutral ➝ Neutral$40.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
10/30/2018The Goldman Sachs GroupReiterated RatingNeutral$45.00Low
i
10/30/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Chris Schott at JPMorgan Chase & Co.
10/23/2018Wolfe ResearchInitiated CoverageMarket PerformLow
i
10/19/2018BarclaysSet Price TargetNeutral$40.00Low
i
10/17/2018Cantor FitzgeraldReiterated RatingBuy$53.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
10/14/2018Credit Suisse GroupSet Price TargetHold$40.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
10/9/2018MorningstarSet Price TargetNeutral$46.00Low
i
10/4/2018Cantor FitzgeraldSet Price TargetBuy$45.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
10/4/2018Independent ResearchSet Price TargetNeutral$48.00Low
i
10/1/2018JPMorgan Chase & Co.Set Price TargetBuy$46.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
9/27/2018MorningstarSet Price TargetBuy$46.00Low
i
9/26/2018BarclaysReiterated RatingNeutral$40.00Low
i
9/26/2018Cantor FitzgeraldSet Price TargetBuy$45.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
9/13/2018Morgan StanleySet Price TargetBuy$45.00Medium
i
Rating by David Risinger at Morgan Stanley
9/13/2018Cantor FitzgeraldSet Price TargetBuy$45.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
9/10/2018JPMorgan Chase & Co.Set Price TargetBuy$42.00Medium
i
9/7/2018BMO Capital MarketsBoost Price TargetOutperform$47.00Medium
i
Rating by Alex Arfaei at BMO Capital Markets
9/6/2018Credit Suisse GroupSet Price TargetHold$40.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
9/6/2018Morgan StanleySet Price TargetBuy$45.00Low
i
Rating by David Risinger at Morgan Stanley
8/29/2018BarclaysSet Price TargetNeutral$40.00Low
i
8/29/2018Morgan StanleySet Price TargetBuy$45.00Low
i
Rating by David Risinger at Morgan Stanley
8/28/2018Credit Suisse GroupSet Price TargetNeutral$40.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
8/28/2018The Goldman Sachs GroupReiterated RatingNeutral$45.00Low
i
8/28/2018MorningstarSet Price TargetBuy$46.00Low
i
8/27/2018BMO Capital MarketsReiterated RatingBuy$44.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
8/27/2018Cantor FitzgeraldSet Price TargetBuy$45.00High
i
Rating by Louise Chen at Cantor Fitzgerald
8/23/2018JPMorgan Chase & Co.Reiterated RatingBuy$42.00Low
i
8/23/2018BarclaysBoost Price TargetEqual Weight ➝ Neutral$38.00 ➝ $40.00Low
i
8/23/2018Morgan StanleySet Price TargetOverweight ➝ Buy$43.00 ➝ $45.00Low
i
Rating by David Risinger at Morgan Stanley
8/21/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$42.00 ➝ $45.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
8/13/2018Cantor FitzgeraldSet Price TargetBuy$45.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
8/10/2018SunTrust BanksBoost Price TargetHold$41.00Low
i
8/8/2018MorningstarSet Price TargetBuy$45.00Low
i
8/1/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$42.00 ➝ $43.00Low
i
8/1/2018The Goldman Sachs GroupReiterated RatingNeutral$42.00Low
i
8/1/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $44.00Medium
i
Rating by Alex Arfaei at BMO Capital Markets
8/1/2018Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$39.00 ➝ $40.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
7/31/2018Jefferies Financial GroupSet Price TargetNeutral$39.00High
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
7/31/2018JPMorgan Chase & Co.Reiterated RatingBuyHigh
i
7/31/2018Credit Suisse GroupSet Price TargetHold$39.00High
i
7/31/2018Cantor FitzgeraldSet Price TargetBuy$45.00High
i
Rating by Louise Chen at Cantor Fitzgerald
7/19/2018BMO Capital MarketsReiterated RatingBuy$42.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
7/18/2018JPMorgan Chase & Co.Reiterated Rating$37.66Medium
i
7/18/2018Cantor FitzgeraldSet Price TargetBuy$45.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
7/15/2018Jefferies Financial GroupSet Price TargetHold$39.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
7/12/2018Credit Suisse GroupSet Price TargetNeutral$39.00Low
i
7/11/2018Cantor FitzgeraldSet Price TargetBuy$45.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
7/11/2018JPMorgan Chase & Co.Reiterated RatingBuy$42.00Low
i
7/9/2018Jefferies Financial GroupReiterated RatingNeutral$39.00Medium
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
6/13/2018Cantor FitzgeraldSet Price TargetBuy$45.00Low
i
Rating by L. Chen at Cantor Fitzgerald
6/11/2018Morgan StanleyReiterated RatingBuy$43.00Low
i
6/11/2018Credit Suisse GroupSet Price TargetNeutral$39.00Low
i
6/7/2018Cantor FitzgeraldInitiated CoverageOverweight$45.00Low
i
Rating by L. Chen at Cantor Fitzgerald
5/30/2018Societe GeneraleReiterated RatingNeutral$39.00Low
i
5/18/2018Credit Suisse GroupReiterated RatingNeutral$39.00Low
i
5/14/2018Jefferies Financial GroupReiterated RatingNeutral$39.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
5/8/2018JPMorgan Chase & Co.Set Price TargetBuy$42.00Low
i
5/3/2018DZ BankReiterated RatingSellLow
i
5/2/2018MorningstarSet Price TargetBuy$43.50Low
i
5/2/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$43.00 ➝ $42.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
5/2/2018JPMorgan Chase & Co.Reiterated RatingBuy$42.00Medium
i
4/13/2018Jefferies Financial GroupSet Price TargetHold$38.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
4/12/2018CitigroupReiterated RatingSellMedium
i
Rating by Andrew Baum at Citigroup Inc.
4/11/2018Berenberg BankReiterated RatingNeutral$37.00Low
i
4/5/2018BarclaysDowngradeOverweight ➝ Equal Weight$41.00 ➝ $38.00Medium
i
4/2/2018BMO Capital MarketsSet Price TargetBuy$43.00Medium
i
Rating by Alex Arfaei at BMO Capital Markets
3/6/2018BMO Capital MarketsSet Price TargetBuy$43.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
2/26/2018Jefferies Financial GroupSet Price TargetHold$39.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
2/15/2018BMO Capital MarketsSet Price TargetBuy$43.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
2/5/2018BMO Capital MarketsSet Price TargetBuy$43.00High
i
Rating by Alex Arfaei at BMO Capital Markets
1/31/2018BarclaysBoost Price TargetOverweight ➝ Overweight$38.00 ➝ $41.00Medium
i
1/31/2018Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$37.00 ➝ $39.00Medium
i
1/31/2018SVB LeerinkBoost Price TargetMarket Perform ➝ Market Perform$35.00 ➝ $38.00Medium
i
1/31/2018UBS GroupSet Price TargetBuy$42.00Medium
i
Rating by Marc Goodman at UBS Group AG
1/31/2018Morgan StanleyBoost Price TargetOverweight ➝ Buy$41.00 ➝ $43.00Medium
i
1/31/2018Societe GeneraleSet Price TargetNeutral$40.00Medium
i
1/30/2018The Goldman Sachs GroupSet Price TargetNeutral$36.00High
i
1/30/2018MorningstarSet Price TargetNeutral$38.00High
i
1/30/2018Bank of AmericaSet Price TargetBuy$40.00Medium
i
Rating by Jason Gerberry at Bank of America Co.
1/30/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
i
1/30/2018Sanford C. BernsteinSet Price TargetBuy$43.00Low
i
1/30/2018Berenberg BankSet Price TargetNeutral$36.00Low
i
1/30/2018BMO Capital MarketsSet Price TargetBuy$39.00High
i
Rating by Alex Arfaei at BMO Capital Markets
1/29/2018SunTrust BanksReiterated RatingHold ➝ Hold$33.00 ➝ $40.00Low
i
1/24/2018BMO Capital MarketsSet Price TargetBuy$39.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
1/16/2018Jefferies Financial GroupSet Price TargetNeutral$40.00Low
i
1/8/2018BMO Capital MarketsSet Price TargetBuy$39.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
1/5/2018Morgan StanleySet Price TargetBuy$41.00Low
i
1/2/2018Nord/LBReiterated RatingNeutralLow
i
12/27/2017Nord/LBReiterated RatingNeutralLow
i
12/15/2017BMO Capital MarketsSet Price TargetBuy$39.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
12/8/2017BMO Capital MarketsSet Price TargetBuy$39.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
12/6/2017UBS GroupSet Price TargetBuy$40.00Low
i
Rating by Marc Goodman at UBS Group AG
12/6/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$38.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
11/25/2017BMO Capital MarketsSet Price TargetBuy$39.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
11/16/2017Jefferies Financial GroupSet Price TargetNeutral$39.00N/A
i
11/10/2017BMO Capital MarketsReiterated RatingBuy$39.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
11/1/2017JPMorgan Chase & Co.Set Price TargetBuy$39.00N/A
i
11/1/2017Jefferies Financial GroupSet Price TargetNeutral$39.00N/A
i
11/1/2017The Goldman Sachs GroupSet Price TargetNeutral$36.00N/A
i
11/1/2017UBS GroupSet Price TargetBuy$38.00N/A
i
Rating by Marc Goodman at UBS Group AG
10/31/2017Berenberg BankSet Price TargetNeutral$36.00N/A
i
10/31/2017BMO Capital MarketsSet Price TargetBuy$39.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/26/2017Jefferies Financial GroupSet Price TargetNeutral$39.00N/A
i
10/19/2017BMO Capital MarketsReiterated RatingBuy$37.00 ➝ $39.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/16/2017Jefferies Financial GroupSet Price TargetNeutral$38.00N/A
i
10/11/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$38.00N/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
10/11/2017BarclaysSet Price TargetBuy$38.00N/A
i
10/10/2017BMO Capital MarketsSet Price TargetBuy$37.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
9/20/2017Morgan StanleyUpgradeEqual Weight ➝ Overweight$35.00 ➝ $39.00Low
i
9/19/2017Sanford C. BernsteinSet Price TargetBuy$39.00Low
i
9/18/2017Jefferies Financial GroupSet Price TargetNeutral$37.00Low
i
9/14/2017BMO Capital MarketsReiterated RatingBuy$37.00High
i
Rating by Alex Arfaei at BMO Capital Markets
9/6/2017BMO Capital MarketsReiterated RatingBuy$37.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
8/24/2017Jefferies Financial GroupSet Price TargetNeutral$35.00Low
i
8/18/2017Jefferies Financial GroupReiterated RatingHold$35.00Low
i
8/15/2017Berenberg BankReiterated RatingHold$39.00 ➝ $36.00Low
i
8/14/2017CowenSet Price TargetBuy$43.00Low
i
Rating by Steve Scala at Cowen Inc
8/2/2017Jefferies Financial GroupSet Price TargetNeutral$35.00Low
i
8/2/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$33.00 ➝ $37.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
8/1/2017Berenberg BankSet Price TargetNeutral$39.00Low
i
7/31/2017UBS GroupReiterated RatingBuy$38.00Medium
i
7/20/2017Credit Suisse GroupDowngradeOutperform ➝ Neutral$38.00 ➝ $36.00Low
i
7/17/2017Sanford C. BernsteinSet Price TargetBuy$39.00Low
i
7/14/2017Jefferies Financial GroupReiterated RatingHold$34.00 ➝ $35.00Low
i
7/10/2017CowenSet Price TargetBuy$43.00Low
i
Rating by Steve Scala at Cowen Inc
6/16/2017Jefferies Financial GroupReiterated RatingNeutral$34.00Low
i
6/12/2017Morgan StanleyReiterated RatingNeutral$38.00 ➝ $35.00Low
i
5/16/2017CitigroupDowngradeNeutral ➝ Sell$38.00 ➝ $31.00Low
i
5/3/2017BarclaysReiterated RatingBuy$38.00Low
i
5/3/2017Sanford C. BernsteinReiterated RatingBuy$37.00Low
i
4/27/2017BMO Capital MarketsReiterated RatingHold$33.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
4/24/2017Sanford C. BernsteinReiterated RatingBuy$35.00Low
i
4/13/2017Jefferies Financial GroupReiterated RatingNeutral$34.00 ➝ $35.00Low
i
4/6/2017Morgan StanleyReiterated RatingNeutral$38.00Low
i
3/24/2017Sanford C. BernsteinReiterated RatingBuy$35.00Low
i
3/23/2017Societe GeneraleReiterated RatingNeutral$36.00Low
i
3/21/2017BMO Capital MarketsReiterated RatingHold$33.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
3/16/2017BarclaysSet Price TargetBuy$38.00Low
i
3/14/2017UBS GroupReiterated RatingBuy$38.00N/A
i
Rating by Marc Goodman at UBS Group AG
3/13/2017Sanford C. BernsteinSet Price TargetBuy$35.00Low
i
3/13/2017Credit Suisse GroupSet Price TargetBuy$38.00Low
i
3/9/2017Jefferies Financial GroupSet Price TargetNeutral$34.00Low
i
2/17/2017Jefferies Financial GroupSet Price TargetNeutral$34.00N/A
i
2/17/2017Berenberg BankSet Price TargetNeutral$39.00N/A
i
2/16/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$40.00N/A
i
2/2/2017MorningstarReiterated RatingBuyN/A
i
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/A
i
1/30/2017BMO Capital MarketsReiterated RatingMarket Perform$33.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
1/24/2017Sanford C. BernsteinSet Price TargetBuy$35.00N/A
i
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$53.00N/A
i
Rating by Richard Purkiss at Piper Jaffray Companies
1/19/2017Jefferies Financial GroupReiterated RatingHold$30.00N/A
i
1/18/2017The Goldman Sachs GroupSet Price TargetNeutral$36.00N/A
i
12/20/2016Credit Suisse GroupReiterated RatingBuy$38.00N/A
i
12/19/2016Jefferies Financial GroupReiterated RatingHold$30.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
12/7/2016Sanford C. BernsteinReiterated RatingOverweightN/A
i
12/2/2016GuggenheimInitiated CoverageNeutralN/A
i
11/30/2016BMO Capital MarketsSet Price TargetHold$33.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
11/29/2016BarclaysUpgradeEqual Weight ➝ Overweight$38.00N/A
i
11/11/2016Jefferies Financial GroupSet Price TargetNeutral$34.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
11/7/2016Bank of AmericaReiterated RatingBuy$40.00 ➝ $36.00N/A
i
Rating by colin bristow at Bank of America Co.
11/3/2016Atlantic SecuritiesSet Price TargetBuy$35.00N/A
i
11/2/2016ArgusDowngradeBuy ➝ HoldN/A
i
Rating by jacob kilstein at Argus
11/2/2016BMO Capital MarketsDowngradeOutperform ➝ Market Perform$40.00 ➝ $33.00N/A
i
11/1/2016Berenberg BankSet Price TargetNeutral$38.00N/A
i
Rating by Alistair Campbell at Berenberg Bank
11/1/2016Sanford C. BernsteinSet Price TargetBuy$36.00N/A
i
10/19/2016Sanford C. BernsteinSet Price TargetBuy$36.00N/A
i
10/18/2016BMO Capital MarketsReiterated RatingOutperform$40.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/13/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$39.00 ➝ $36.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
10/4/2016ArgusReiterated RatingBuy$39.00N/A
i
Rating by jacob kilstein at Argus
9/30/2016UBS GroupSet Price TargetBuy$38.00N/A
i
Rating by Steven Milunovich at UBS Group AG
9/27/2016Bank of AmericaReiterated RatingBuy$40.00N/A
i
Rating by colin bristow at Bank of America Co.
9/26/2016Sanford C. BernsteinReiterated RatingOutperformN/A
i
Rating by Tim Anderson at Sanford C. Bernstein
9/13/2016Jefferies Financial GroupLower Price TargetBuy$40.00 ➝ $39.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
9/7/2016UBS GroupReiterated RatingBuyN/A
i
Rating by Steven Milunovich at UBS Group AG
8/28/2016ArgusReiterated RatingBuy$39.00N/A
i
Rating by jacob kilstein at Argus
8/25/2016Jefferies Financial GroupSet Price TargetBuy$40.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
8/23/2016Piper Jaffray CompaniesSet Price TargetBuy$54.00N/A
i
Rating by richard purkiss at Piper Jaffray Companies
8/23/2016BMO Capital MarketsReiterated RatingOutperform$40.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
8/22/2016Bank of AmericaSet Price TargetBuy$40.00N/A
i
Rating by colin bristow at Bank of America Co.
8/22/2016Credit Suisse GroupReiterated RatingOutperform$40.00N/A
i
8/18/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$44.00N/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
8/3/2016JPMorgan Chase & Co.Set Price TargetBuy$40.00N/A
i
Rating by Chris Schott at JPMorgan Chase & Co.
8/3/2016CitigroupReiterated RatingNeutral$37.00N/A
i
8/2/2016BarclaysReiterated RatingEqual Weight$34.00N/A
i
8/2/2016Sanford C. BernsteinSet Price TargetBuy$38.00N/A
i
Rating by Tim Anderson at Sanford C. Bernstein
8/1/2016Jefferies Financial GroupSet Price TargetBuy$41.50 ➝ $40.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
7/25/2016Piper Jaffray CompaniesSet Price TargetBuy$54.00N/A
i
Rating by Richard Purkiss at Piper Jaffray Companies
7/25/2016JPMorgan Chase & Co.Set Price TargetBuy$40.00N/A
i
Rating by Chris Schott at JPMorgan Chase & Co.
7/21/2016BMO Capital MarketsReiterated RatingBuy$40.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
7/14/2016Jefferies Financial GroupSet Price TargetBuy$40.00 ➝ $41.50N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
6/27/2016Piper Jaffray CompaniesReiterated RatingOverweight$54.00N/A
i
6/20/2016Jefferies Financial GroupLower Price TargetBuy$42.00 ➝ $40.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
6/15/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
6/14/2016Jefferies Financial GroupReiterated RatingBuy$41.00 ➝ $42.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
5/19/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
i
Rating by Chris Schott at JPMorgan Chase & Co.
5/17/2016Morgan StanleyReiterated RatingHold$36.00N/A
i
Rating by David Risinger at Morgan Stanley
5/12/2016Berenberg BankInitiated CoverageHold$38.00N/A
i
5/11/2016Jefferies Financial GroupSet Price TargetBuy$41.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
5/10/2016Bank of AmericaReiterated RatingBuy$38.48 ➝ $28.25N/A
i
Rating by Colin Bristow at Bank of America Co.
5/10/2016UBS GroupSet Price TargetBuy$38.00N/A
i
Rating by Steven Milunovich at UBS Group AG
5/9/2016The Goldman Sachs GroupSet Price TargetNeutral$37.00N/A
i
5/9/2016Morgan StanleySet Price TargetNeutral$36.00N/A
i
Rating by David Risinger at Morgan Stanley
5/9/2016Credit Suisse GroupBoost Price TargetOutperform$38.00 ➝ $39.00N/A
i
5/4/2016BMO Capital MarketsReiterated RatingBuy$39.00 ➝ $40.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
5/4/2016UBS GroupBoost Price TargetBuy$36.00 ➝ $38.00N/A
i
5/4/2016Independent ResearchSet Price TargetNeutral$37.00N/A
i
5/4/2016Societe GeneraleSet Price TargetNeutral$34.00N/A
i
5/3/2016Sanford C. BernsteinSet Price TargetBuy$36.00N/A
i
Rating by Tim Anderson at Sanford C. Bernstein
5/2/2016SVB LeerinkLower Price TargetMarket Perform$37.00 ➝ $34.70N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
4/28/2016BMO Capital MarketsReiterated RatingBuyN/A
i
4/18/2016The Goldman Sachs GroupReiterated RatingNeutral$35.00N/A
i
4/12/2016S&P Equity ResearchReiterated RatingBuyN/A
i
Rating by Jeffrey Loo at S&P Equity Research
4/7/2016Independent ResearchSet Price TargetNeutral$35.00N/A
i
4/7/2016Morgan StanleyInitiated CoverageOverweight ➝ Equal Weight$35.00N/A
i
4/7/2016JPMorgan Chase & Co.Initiated CoverageOverweight$38.00N/A
i
4/6/2016Societe GeneraleInitiated CoverageHold$33.00N/A
i
4/5/2016BMO Capital MarketsReiterated RatingOutperform$39.00N/A
i
4/5/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Jason Gerberry at SVB Leerink LLC
4/5/2016Jefferies Financial GroupReiterated RatingBuy$42.00 ➝ $39.00N/A
i
4/5/2016Sanford C. BernsteinReiterated RatingBuy$36.00N/A
i
3/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$54.00N/A
i
Rating by Richard Purkiss at Piper Jaffray Companies
3/8/2016Jefferies Financial GroupReiterated RatingBuy$45.00 ➝ $42.00N/A
i
2/22/2016Jefferies Financial GroupLower Price TargetBuy$45.00N/A
i
2/16/2016SunTrust BanksLower Price TargetNeutral$37.00 ➝ $33.00N/A
i
Rating by John Boris at SunTrust Banks, Inc.
2/11/2016ArgusBoost Price TargetBuy$32.00 ➝ $39.00N/A
i
2/10/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
2/9/2016Bank of AmericaUpgradeBuy ➝ Top Pick$39.00N/A
i
2/5/2016Credit Suisse GroupLower Price Target$41.00 ➝ $38.00N/A
i
2/5/2016Piper Jaffray CompaniesReiterated RatingOverweight$23.00N/A
i
Rating by Richard Purkiss at Piper Jaffray Companies
2/3/2016Independent ResearchSet Price TargetNeutral$34.00N/A
i
2/3/2016Deutsche Bank AktiengesellschaftLower Price TargetBuy$43.00 ➝ $41.00N/A
i
2/3/2016Sanford C. BernsteinLower Price TargetOutperform$41.00 ➝ $36.00N/A
i
2/3/2016BMO Capital MarketsReiterated RatingOutperform$41.00 ➝ $39.00N/A
i
1/26/2016Nord/LBReiterated RatingBuyN/A
i
1/15/2016UBS GroupSet Price TargetBuy$36.00N/A
i
(Data available from 1/15/2016 forward)
Pfizer logo
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; a licensing agreement with Akcea Therapeutics, Inc; a strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; a clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; a material transfer and collaboration agreement with BioNTech SE; a clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; a research collaboration and license agreement with BioInvent International AB; a drug discovery collaboration with Sosei Group Corporation; and collaboration with LianBio. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $36.75
$36.61
$36.96

50 Day Range

MA: $38.26
$36.53
$42.56

52 Week Range

Now: $36.75
$27.88
$43.08

Volume

30,271,992 shs

Average Volume

35,117,566 shs

Market Capitalization

$204.27 billion

P/E Ratio

14.58

Dividend Yield

4.12%

Beta

0.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Pfizer?

The following Wall Street analysts have issued reports on Pfizer in the last twelve months: Atlantic Securities, Barclays PLC, Berenberg Bank, Cantor Fitzgerald, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, Standpoint Research, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Truist, UBS Group AG, and Zacks Investment Research.

What is the current price target for Pfizer?

14 Wall Street analysts have set twelve-month price targets for Pfizer in the last year. Their average twelve-month price target is $40.07, suggesting a possible upside of 9.0%. Cantor Fitzgerald has the highest price target set, predicting PFE will reach $53.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $24.00 for Pfizer in the next year.

What is the current consensus analyst rating for Pfizer?

Pfizer currently has 10 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PFE, but not buy more shares or sell existing shares.

What other companies compete with Pfizer?

How do I contact Pfizer's investor relations team?

Pfizer's physical mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company's listed phone number is 212-733-2323. The official website for Pfizer is www.pfizer.com.